Table 2.
Multivariate analysis of all-cause mortality in patients with breast cancer who received neoadjuvant chemotherapy followed by total mastectomy.
| All-cause mortality |
||||
|---|---|---|---|---|
| HR | (95% CI) | p value | ||
| PMRT | No | Ref | 0.0001 | |
| Yes | 0.71 | (0.56–0.77) | ||
| Age | 20–49 | Ref | 0.59 | |
| 50+ | 1.02 | (0.89–1.16) | ||
| Diagnosis year | 2007–2010 | Ref | 0.88 | |
| 2011–2015 | 0.97 | (0.89–1.11) | ||
| CCI scores | 0 | Ref | 0.0004 | |
| 1 | 0.91 | (0.73–1.11) | ||
| 2+ | 1.54 | (1.24–1.90) | ||
| Differentiation | Poor | Ref | <0.0001 | |
| Moderate | 0.73 | (0.66–0.86) | ||
| Well | 0.43 | (0.32–0.61) | ||
| AJCC clinical stages | I | Ref | <0.0001 | |
| II | 1.86 | (0.92–2.88) | ||
| III | 2.08 | (1.29–3.77) | ||
| IV | 2.80 | (1.44–3.75) | ||
| ypT | ypT0 | Ref | <0.0001 | |
| ypT1 | 1.59 | (1.11–2.32) | ||
| ypT2 | 1.79 | (1.22–1.98) | ||
| ypT3–4 | 2.59 | (2.01–3.70) | ||
| ypN | ypN0 | Ref | <0.0001 | |
| ypN1 | 1.44 | (1.16–1.84) | ||
| ypN2–3 | 2.33 | (2.01–2.77) | ||
| NACT regimen | Anthracycline | Ref | 0.39 | |
| Taxanes | 1.10 | (0.93–1.29) | ||
| Both | 1.04 | (0.87–1.20) | ||
| Neither | 1.13 | (0.89–1.37) | ||
| Nodal surgery | SLNB | Ref | 0.88 | |
| ALND | 1.07 | (0.89–1.33) | ||
| ER/PR | Negative | Ref | <0.0001 | |
| Positive | 0.65 | (0.55–0.74) | ||
| HER2 positive | Negative | Ref | 0.88 | |
| Positive | 1.02 | (0.88–1.14) | ||
| Hospital level | Academic | Ref | 0.29 | |
| Others | 0.91 | (0.82–1.07) | ||
HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiation therapy; T, tumor; N, nodal; NACT, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; ypT, postchemotherapy pathologic tumor stages; ypN, postchemotherapy pathologic nodal stages.